Jubilant Pharmova Limited Market Cap ($1.58 Billion)
Market Cap & Net Worth: Jubilant Pharmova Limited (JUBLPHARMA)
Jubilant Pharmova Limited market cap. Jubilant Pharmova Limited (NSE:JUBLPHARMA) has a market capitalization of $1.58 Billion (Rs146.32 Billion) as of October 31, 2026. Listed on the NSE stock exchange, this India-based company holds position #6739 globally and #313 in its home market, demonstrating a -0.90% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jubilant Pharmova Limited's stock price Rs923.80 by its total outstanding shares 158387168 (158.39 Million).
Jubilant Pharmova Limited Market Cap History (2015–2026)
Jubilant Pharmova Limited market cap history from 2015 to 2026. Data shows growth from $564.68 Million to $1.58 Billion (10.33% CAGR). Check JUBLPHARMA share price today for real-time trading data and today's change.
Index Memberships
Jubilant Pharmova Limited is a constituent of 5 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$2.93 Trillion | 0.05% | #269 of 500 |
|
NIFTY ALHPA 50
NIFTYALI
|
$314.41 Billion | 0.50% | #24 of 47 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.06 Trillion | 0.15% | #182 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.02 Trillion | 0.05% | #270 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$378.13 Billion | 0.42% | #85 of 250 |
Weight: Jubilant Pharmova Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jubilant Pharmova Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jubilant Pharmova Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see JUBLPHARMA cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.03x
Jubilant Pharmova Limited's market cap is 0.03 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.22x
Jubilant Pharmova Limited's market cap is 0.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $865.85 Million | $57.49 Billion | $3.92 Billion | 0.02x | 0.22x |
| 2017 | $1.09 Billion | $58.61 Billion | $5.76 Billion | 0.02x | 0.19x |
| 2018 | $989.00 Million | $75.18 Billion | $6.43 Billion | 0.01x | 0.15x |
| 2019 | $757.07 Million | $91.11 Billion | $5.74 Billion | 0.01x | 0.13x |
| 2020 | $1.20 Billion | $59.76 Billion | $8.98 Billion | 0.02x | 0.13x |
| 2021 | $970.90 Million | $60.99 Billion | $8.36 Billion | 0.02x | 0.12x |
| 2022 | $630.31 Million | $61.30 Billion | $4.14 Billion | 0.01x | 0.15x |
| 2023 | $927.51 Million | $62.82 Billion | -$610.00 Million | 0.01x | N/A |
| 2024 | $1.89 Billion | $67.03 Billion | $771.00 Million | 0.03x | 2.46x |
| 2025 | $1.84 Billion | $72.34 Billion | $8.39 Billion | 0.03x | 0.22x |
Competitor Companies of JUBLPHARMA by Market Capitalization
Companies near Jubilant Pharmova Limited in the global market cap rankings as of October 31, 2026. See JUBLPHARMA equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Jubilant Pharmova Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Jubilant Pharmova Limited (2015–2026)
Market capitalization of Jubilant Pharmova Limited from 2015 to today. Between 2015 and today, Jubilant Pharmova Limited's market cap moved from $564.68 Million to $ 1.58 Billion, with a yearly change of 10.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs1.58 Billion | -13.93% |
| 2025 | Rs1.84 Billion | -2.89% |
| 2024 | Rs1.89 Billion | +104.11% |
| 2023 | Rs927.51 Million | +47.15% |
| 2022 | Rs630.31 Million | -35.08% |
| 2021 | Rs970.90 Million | -19.19% |
| 2020 | Rs1.20 Billion | +58.70% |
| 2019 | Rs757.07 Million | -23.45% |
| 2018 | Rs989.00 Million | -9.52% |
| 2017 | Rs1.09 Billion | +26.24% |
| 2016 | Rs865.85 Million | +53.33% |
| 2015 | Rs564.68 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Jubilant Pharmova Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.58 Billion USD |
| MoneyControl | $1.58 Billion USD |
| MarketWatch | $1.58 Billion USD |
| marketcap.company | $1.58 Billion USD |
| Reuters | $1.58 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more